Cargando…

Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis

BACKGROUND: With a large array of disease modifying therapies (DMTs) for relapsing-remitting MS (RRMS), identifying the optimal treatment option for the individual patient is challenging and switching of immunotherapies is often required. The objective of this study was to systematically investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mäurer, Mathias, Tiel-Wilck, Klaus, Oehm, Eckard, Richter, Nils, Springer, Michael, Oschmann, Patrick, Manzel, Arndt, Hieke-Schulz, Stefanie, Zingler, Vera, Kandenwein, Julia A., Ziemssen, Tjalf, Linker, Ralf A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923693/ https://www.ncbi.nlm.nih.gov/pubmed/31903096 http://dx.doi.org/10.1177/1756286419892077

Ejemplares similares

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol
por: Dirks, Petra, et al.
Publicado: (2020)

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol
por: Vormfelde, Stefan Viktor, et al.
Publicado: (2016)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

101 reasons: to switch to the Mac
por: McElroy, Mark
Publicado: (2006)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2008)

Vascular pathology in multiple sclerosis: mind boosting or myth busting?
por: Waschbisch, Anne, et al.
Publicado: (2011)

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
por: Manica, Santiago Rodrigues, et al.
Publicado: (2020)

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study
por: Weber, Martin S., et al.
Publicado: (2022)

Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients
por: Schriefer, Dirk, et al.
Publicado: (2020)

Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy
por: Almouzain, Lubna, et al.
Publicado: (2021)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
por: Suhling, Hendrik, et al.
Publicado: (2023)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial
por: Ziemssen, Focke, et al.
Publicado: (2020)

Transition from Methylphenidate to Atomoxetine: reasons for switching and clinical outcome
por: Cassar, Fabrizia, et al.
Publicado: (2021)

Phonological Fluency Strategy of Switching Differentiates Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Patients
por: Messinis, L., et al.
Publicado: (2013)

Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study
por: Linker, Ralf A., et al.
Publicado: (2016)

Filtration Group switches part of German production to face masks
Publicado: (2020)

Code-Switching Does Not Equal Code-Switching. An Event-Related Potentials Study on Switching From L2 German to L1 Russian at Prepositions and Nouns
por: Zeller, Jan Patrick
Publicado: (2020)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Commentary: What switch, to switch or not to switch: That is the question!
por: Kavarana, Minoo N.
Publicado: (2020)

Changes in drug load during lacosamide combination therapy: A noninterventional, observational study in German and Austrian clinical practice
por: Reinhardt, Fritjof, et al.
Publicado: (2019)

Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III
por: Bach, Thorsten, et al.
Publicado: (2016)

Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR
por: Schulz, Felicitas, et al.
Publicado: (2023)

Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria
por: Guger, Michael, et al.
Publicado: (2022)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

A transcriptional switch controls meiosis
por: Hildreth, A Elizabeth, et al.
Publicado: (2017)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Role of glial 14-3-3 gamma protein in autoimmune demyelination
por: Lee, De-Hyung, et al.
Publicado: (2015)

Survey of smokers' reasons for not switching to safer sources of nicotine and their willingness to do so in the future
por: Heavner, Karyn K, et al.
Publicado: (2009)

Working Memory, Reasoning, and Task Switching Training: Transfer Effects, Limitations, and Great Expectations?
por: Baniqued, Pauline L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k1cit1d5dqepb4j07igmhob16f